Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular Cancer

New England Journal of Medicine

Volumn 317, Issue 23, 1987, Pages 1433-1438

  Williams, Stephen D ^{a,b,c,d,e,f,g,h,i}   Stablein, Donald M ^{a,b,c,d,e,f,g,h,i}   Einhorn, Lawrence H ^{a,b,c,d,e,f,g,h,i}   Muggia, Franco M ^{a,b,c,d,e,f,g,h,i}   Weiss, Raymond B ^{a,b,c,d,e,f,g,h,i}   Donohue, John P ^{a,b,c,d,e,f,g,h,i}   Paulson, David F ^{a,b,c,d,e,f,g,h,i}   Brunner, Kurt W ^{a,b,c,d,e,f,g,h,i}   Jacobs, Edwin M ^{a,b,c,d,e,f,g,h,i}   Spaulding, Joseph T ^{a,b,c,d,e,f,g,h,i}   Dewys, William D ^{a,b,c,d,e,f,g,h,i}   Crawford, E David ^{a,b,c,d,e,f,g,h,i}  

^a INDIANA UNIVERSITY   (United States)

^b EMMES CORPORATION   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h KAISER PERMANENTE MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; VINBLASTINE;

CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE GENITAL SYSTEM; TESTIS CANCER; THERAPY;

EID: 0023243140     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198712033172303     Document Type: Article

References (22)

1. Hainsworth JD, Greco FA. Testicular germ cell neoplasms. Am J Med 1983; 75: 817–32.
2. Williams SD. Einhorn LH. Clinical stage I testis tumors: the medical oncologist's view. Cancer Treat Rep 1982; 66: 15–8.
3. Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 1981; 305: 727–31.
4. Bosl GJ, Gluckman R, Geller NL, et al. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 1986; 4: 1493–9.
5. Birch R, Williams S, Cone A, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4: 400–7.
6. Vogelzang NJ, Fraley EE, Lange PH, Torkelson J, Levitt S, Kennedy BJ. Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol 1983; 1: 171–8.
7. Pizzocaru G, Monfardini S. No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol 1984; 131: 677–80.
8. Bredael JJ, Vugrin D, Whitmore WF Jr. Selected experience with surgery and combination chemotherapy in the treatment of nonseminomatous testis tumors. J Urol 1983; 129: 985–8.
9. Samuels ML, Johnson DE. Adjuvant therapy of testis cancer: the role of vinblastine and bleomycin. J Urol 1980; 124: 369–71.
10. Dewys WD, Green SB, Einhorn LH, Hahn RG, Brunner KW, Williams SD. Adjuvant chemotherapy of testicular cancer. In: Jones SE, Salmon SE, eds. Adjuvant therapy of cancer IV. Orlando, Fla.: Grune & Stratton, 1984:529–37.
11. Weiss RB, Stablein DM, Muggia FM, et al. Toxicity of chemotherapy as adjuvant or salvage treatment in early stage non-seminomatous testicular cancer. Proc Am Soc Clin Oncol 1986; 5: 99. abstract.
12. Reynolds TF, Vugrin D, Cvitkovic E, et al. VAB-3 combination chemotherapy of metastatic testicular cancer. Cancer 1981; 48: 888–98.
13. Whitmore WF Jr. Surgical treatment of clinical stage I nonseminomatous germ cell tumors of the testis. Cancer Treat Rep 1982; 66: 5–10.
14. Vugrin D, Whitmore WF, Cvitkovic E, et al. Adjuvant chemotherapy combination of vinblastine, actinomycin D, bleomycin, and chlorambucil following retroperitoneal lymph node dissection for stage II testis tumor. Cancer 1981; 47: 840–4.
15. Vugrin D, Whitmore W, Cvitkovic E, Grabstald H, Sogani P, Golbey RB. Adjuvant chemotherapy with VAB-3 of stage II-B testicular cancer. Cancer 1981; 48: 233–7.
16. Vugrin D, Whitmore WF Jr, Herr HW, Sogani P, Golbey RB. VAB-6 combination chemotherapy in resected stage II-B testis cancer. Cancer 1983; 51: 5–8.
17. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1981; 128: 315–20.
18. Raghavan D, Vogelzang NJ, Bosl GJ, et al. Tumor classification and size in germ-cell testicular cancer: influence on the occurrence of metastases. Cancer 1982; 50: 1591–5.
19. Rodriguez PN, Hafez GR, Messing EM. Nonseminomatous germ cell tumor of the testicle: Does extensive staging of the primary tumor predict the likelihood of metastatic disease? J Urol 1986; 136: 604–8.
20. von der Maase H, Berthelsen JG, Jacobsen GK, et al. Carcinoma-in-situ of testis eradicated by chemotherapy. Lancet 1985; 1: 98.
21. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435–40.
22. Bosl GJ, Bajorin D, Leitner S. A randomized trial of etoposide plus cisplatin and VAB-6 in the treatment of “good risk” patients with germ cell tumors. Proc Am Soc Clin Oncol 1986; 5: 104. abstract.